Candel Therapeutics, Inc.

NASDAQ
CADL
Stock
Yield per half year: +26.25%
Dividend yield: 0%
Sector: Healthcare

Share chart Candel Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

more details
It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2021-07-27
ISIN US1374041093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 5.43
Change price per day: +6.07% (5.6)
Change price per week: +9.59% (5.42)
Change price per month: +22.73% (4.84)
Change price per 3 month: -30.93% (8.6)
Change price per half year: +26.25% (4.705)
Change price per year: -31.09% (8.62)
Change price per 3 year: +57.14% (3.78)
Change price per year to date: -33.03% (8.87)
All parameters

Grade

Underestimation
Title Value Grade
P/S 1064.07 1
P/BV 4.15 4
P/E 0 0
EV/EBITDA -5.49 0
Total: 3
Efficiency
Title Value Grade
ROA, % -74.53 0
ROE, % -139.56 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.3257 10
Total: 8.8
Growth impulse
Title Value Grade
Yield Revenue, % -75.2 0
Yield Ebitda, % 292.6 10
Yield EPS, % 47.01 6
Total: 7.2
More

Main owners

Institutions Volume Share, %
Northpond Ventures, Llc 1 935 215 6.59
Sands Capital Ventures, LLC 811 737 2.77
Vanguard Group Inc 425 749 1.45
FMR, LLC 298 384 1.02
Geode Capital Management, LLC 139 253 0.47
Bridgeway Capital Management, Inc. 132 595 0.45
Baystate Wealth Management LLC 76 910 0.26
Blackrock Inc. 49 285 0.17
OneDigital Investment Advisors LLC 29 783 0.1
State Street Corporation 27 600 0.09

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer 335.27k 1968 (57 years)
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 506.76k 1978 (47 years)
Ms. Ileen B. Winick Chief People Officer N/A
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer N/A 1961 (64 years)
Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer N/A 1969 (56 years)
Mr. Charles Schoch Interim CFO, Principal Accounting Officer, Treasurer & Secretary N/A 1985 (40 years)
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, CEO & Director 1961 (64 years)

About company

Address: United States, Needham. MA, 117 Kendrick Street - Open in google maps, Open in yandex maps
Website: https://www.candeltx.com